Mr. Raineri has more than 25 years of experience in the industry, serving most recently as the chief manufacturing and technology officer at Avrobio, according to an Oct. 19 news release from Aspen. In his new role, Mr. Raineri will be responsible for developing the strategy for the company’s cell therapy portfolio.
“This is an important milestone for Aspen Neuroscience and Kim is an integral part of the team that will bring our products to market,” company President and CEO Damien McDevitt, PhD, said in the release. “Aspen is entering an historic new stage of growth, as the first company in the world to reach this stage of development, where we are manufacturing autologous PD patient iPSCs for use in upcoming clinical trials.”
